Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 2 4 IN PLASTIC CONTAINER versus CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 2 4 IN PLASTIC CONTAINER versus CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER.
CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER vs CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis.
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It has bactericidal activity against a broad range of gram-positive and gram-negative bacteria.
1-2 g IV every 6-8 hours; maximum 12 g/day.
1-2 g intravenously or intramuscularly every 24 hours. Maximum dose: 4 g daily.
None Documented
None Documented
0.8-1.4 hours (normal renal function); ~2-6 hours in renal impairment; prolonged in neonates and elderly
Terminal elimination half-life is approximately 5.8-8.7 hours in adults, prolonged to 12-24 hours in elderly, and up to 30-72 hours in neonates. No dose adjustment in renal impairment alone; adjust in severe hepatic impairment.
Renal: 50-60% unchanged; biliary: 20-30%; fecal: <5%
Renal (33-67% unchanged) and biliary (up to 40% as unchanged drug and microbiologically inactive metabolites); fecal elimination of unabsorbed drug is minimal. Dose adjustment required in combined renal and hepatic impairment.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic